Inzidenz und prognostische Bedeutung der Mutation p.L265P im MYD88-Gen bei Patienten mit Multiplem Myelom

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-06-14

• Fields of study

  Not labeled

• Identifiers
  DOI 10.18725/OPARU-4386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma

  2015cited by this paper
• Ibrutinib in previously treated Waldenström's macroglobulinemia.

  2015cited by this paper
• One-step molecular detection of the MYD88 L265P mutation by unlabeled probe genotyping analysis.

  2015cited by this paper
• The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

  2015cited by this paper
• Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

  2014cited by this paper
• MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia

  2014cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.

  2014cited by this paper
• Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with Waldenström's Macroglobulinemia: Correlation with MYD88 L265P Somatic Mutation Status, Clinical Features, and Outcome

  2014cited by this paper
• A Diagnostic Approach to Patients with an IgM Monoclonal Protein

  2014cited by this paper
• MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

  2014cited by this paper
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

  2014cited by this paper
• The Genetic Architecture of Multiple Myeloma

  2014cited by this paper
• Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

  2014cited by this paper
• Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

  2013cited by this paper
• Multiple myeloma: an update.

  2013influential reference
• L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma

  2013influential reference
• MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

  2013influential reference
• Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.

  2013cited by this paper
• MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.

  2013cited by this paper
• IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

  2013influential reference
• The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

  2013cited by this paper
• Improved accuracy of discrimination between IgM Multiple Myeloma and Waldenström Macroglobulinaemia by testing for MYD88 L265P mutations

  2013cited by this paper
• A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

  2013cited by this paper
• MYD88 L265P somatic mutation in IgM MGUS.

  2012influential reference
• MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.

  2012cited by this paper
• Molecular pathogenesis of Waldenström’s macroglobulinemia

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012influential reference
• Absence of MYD88 gene mutation in acute leukemias and multiple myelomas

  2012cited by this paper
• MYD88 L265P mutation in Waldenstrom macroglobulinemia.

  2012cited by this paper
• Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.

  2012cited by this paper
• Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

  2011cited by this paper
• Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

  2011cited by this paper
• The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

  2011cited by this paper
• Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

  2011cited by this paper
• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

  2011cited by this paper
• Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

  2011cited by this paper
• Oncogenically active MYD88 mutations in human lymphoma

  2011influential reference
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

  2010cited by this paper
• A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

  2010cited by this paper
• Oncogenic activation of NF-kappaB.

  2010cited by this paper
• Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

  2010cited by this paper
• Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• Pathogenesis of myeloma bone disease

  2009cited by this paper
• MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

  2009cited by this paper
• Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

  2009cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

  2009cited by this paper
• How I treat Waldenström macroglobulinemia.

  2009cited by this paper
• High‐Resolution Melting Analysis (HRMA)—More than just sequence variant screening

  2009cited by this paper
• Targeting NF-kappaB in Waldenstrom macroglobulinemia.

  2008cited by this paper
• Pathogenesis and treatment of renal failure in multiple myeloma

  2008cited by this paper
• Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

  2008cited by this paper
• Familial myeloma.

  2008cited by this paper
• Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

  2007cited by this paper
• [Survival analysis: Cox regression].

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

  2007cited by this paper
• Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

  2007cited by this paper
• The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

  2007influential reference
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

  2007cited by this paper
• Cytogenetics and molecular cytogenetics in multiple myeloma.

  2006cited by this paper
• Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY

  2006cited by this paper
• Competence and competition: the challenge of becoming a long-lived plasma cell

  2006cited by this paper
• Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population‐based case‐control study

  2006cited by this paper
• Ubiquitin signalling in the NF-kappaB pathway.

  2005influential reference
• Anthropometric Characteristics and Risk of Multiple Myeloma

  2005cited by this paper
• Molecular pathogenesis and a consequent classification of multiple myeloma.

  2005influential reference
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• International staging system for multiple myeloma.

  2005influential reference
• [Survival analysis - the log rank test].

  2005cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

  2004cited by this paper
• Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report

  2004cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

  2003cited by this paper
• Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003influential reference
• Monoclonal gammopathies of undetermined significance: a review

  2003cited by this paper
• Clinical and biologic implications of recurrent genomic aberrations in myeloma.

  2003cited by this paper
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

  2003cited by this paper
• New insights into the pathophysiology of multiple myeloma.

  2003influential reference
• Re: familial multiple myeloma: a family study and review of the literature.

  2002cited by this paper
• Genomic abnormalities in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Multiple myeloma: evolving genetic events and host interactions

  2002cited by this paper
• Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

  2001cited by this paper
• Hypodiploidy is a major prognostic factor in multiple myeloma.

  2001cited by this paper
• Chromosome translocations in multiple myeloma

  2001influential reference
• Mechanisms of chromosomal translocations in B cell lymphomas

  2001cited by this paper
• High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

  2001cited by this paper
• Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

  2000cited by this paper
• Multiple myeloma and renal failure.

  2000cited by this paper
• Aberrant rel/nfkb genes and activity in human cancer

  1999cited by this paper
• Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.

  1999cited by this paper

• No citing papers are available for this paper.